Ronald B. Moss
Director/Board Member chez Biosortia Pharmaceuticals, Inc.
Fortune : 150 $ au 31/03/2024
Profil
Ronald B.
Moss is currently a Director at Biosortia Pharmaceuticals, Inc. He was previously the President & Chief Executive Officer at Orchestra Therapeutics, Inc. and Ansun Biopharma, Inc. He also held positions as Senior Director-Worldwide Regulatory Affairs at Merck & Co., Inc., Assistant Medical Director at Immunization Products Ltd., Vice President-Clinical Development at Vical, Inc., Clinical Associate-Allergy & Clinical Immunology at National Institutes of Health, and Vice President-Medical Affairs at Telos Pharmaceuticals LLC.
Dr. Moss received his undergraduate degree from Stony Brook University and his doctorate from Rosalind Franklin University of Medicine & Science and Chicago Medical School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 06/10/2023 | 2 884 ( 0,03% ) | 150 $ | 31/03/2024 |
Postes actifs de Ronald B. Moss
| Sociétés | Poste | Début |
|---|---|---|
Biosortia Pharmaceuticals, Inc.
 Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | Director/Board Member | - |
Anciens postes connus de Ronald B. Moss
| Sociétés | Poste | Fin |
|---|---|---|
| DMK PHARMACEUTICALS CORPORATION | Chief Tech/Sci/R&D Officer | 14/10/2022 |
Ansun Biopharma, Inc.
 Ansun Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ansun Biopharma, Inc. manufactures pharmaceutical products. Its products include Fludase, a drug candidate for the prophylaxis and treatment of respiratory infections caused by various types of influenza virus, including the types of virus that may cause a potential influenza pandemic, as well as various types of parainfluenza virus. The company was founded by Nancy Chang on August 9, 2012 and is headquartered in San Diego, CA. | Chief Executive Officer | 01/02/2017 |
Vical, Inc.
 Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Chief Tech/Sci/R&D Officer | 01/01/2009 |
| Telos Pharmaceuticals LLC | Chief Tech/Sci/R&D Officer | 01/03/2006 |
| MERCK & CO., INC. | General Counsel | 01/01/2004 |
Formation de Ronald B. Moss
| Stony Brook University | Undergraduate Degree |
| Rosalind Franklin University of Medicine & Science | Doctorate Degree |
| Chicago Medical School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| DMK PHARMACEUTICALS CORPORATION | Health Technology |
| Entreprise privées | 7 |
|---|---|
Vical, Inc.
Vical, Inc. Pharmaceuticals: MajorHealth Technology Vical, Inc. engages in the research and development of biopharmaceutical products based on patented DNA delivery technologies for the prevention and treatment of serious and life-threatening diseases. It focuses on the antifungal VL-2397, which treats patients with invasive aspergillosis. Its products include Vaxfectin, a cationic lipid formulation optimized to increase the immune response to vaccines. The company was founded by Howard E. Greene, Jr. Timothy J. Wollaeger, Karl Y. Hostetler, and Douglas D. Richman in April 1987 and is headquartered in San Diego, CA. | Health Technology |
Orchestra Therapeutics, Inc.
 Orchestra Therapeutics, Inc. Financial ConglomeratesFinance Orchestra Therapeutics, Inc. operates as a development stage company. It previously operated as an immuno-pharmaceutical company focused on developing products to treat autoimmune diseases. The company was founded in 1986 and is headquartered in Carlsbad, CA. | Finance |
Biosortia Pharmaceuticals, Inc.
Biosortia Pharmaceuticals, Inc. BiotechnologyHealth Technology Biosortia Pharmaceuticals, Inc. engages as a researching and developing algal technology company. It focuses on commercialization of concentration, dewatering, drying, and extraction of biomass. The company was founded by Ross O. Youngs in 2008 and is headquartered in Columbus, OH. | Health Technology |
National Institutes of Health
 National Institutes of Health General GovernmentGovernment National Institutes Of Health conducts & supports peer-reviewed medical research and science. The firm's scientists & researchers investigate on different ways to prevent diseases as well as the causes, treatments and cures for common and rare diseases. The company was founded in 1887 and is headquartered in Bethesda, MD. | Government |
| Telos Pharmaceuticals LLC | |
| Immunization Products Ltd. | |
Ansun Biopharma, Inc.
Ansun Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ansun Biopharma, Inc. manufactures pharmaceutical products. Its products include Fludase, a drug candidate for the prophylaxis and treatment of respiratory infections caused by various types of influenza virus, including the types of virus that may cause a potential influenza pandemic, as well as various types of parainfluenza virus. The company was founded by Nancy Chang on August 9, 2012 and is headquartered in San Diego, CA. | Health Technology |
